352 related articles for article (PubMed ID: 12761347)
1. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
[TBL] [Abstract][Full Text] [Related]
2. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
3. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
6. Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms.
Rybalkina IG; Tang XB; Rybalkin SD
Mol Pharmacol; 2010 Apr; 77(4):670-7. PubMed ID: 20086037
[TBL] [Abstract][Full Text] [Related]
7. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
8. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
10. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
11. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
Zoraghi R; Corbin JD; Francis SH
J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
[TBL] [Abstract][Full Text] [Related]
14. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
16. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices.
Rutten K; Vente JD; Sik A; Ittersum MM; Prickaerts J; Blokland A
Behav Brain Res; 2005 Oct; 164(1):11-6. PubMed ID: 16076505
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
18. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.
Gopal VK; Francis SH; Corbin JD
Eur J Biochem; 2001 Jun; 268(11):3304-12. PubMed ID: 11389733
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibitor sensitivity between human recombinant and native photoreceptor cGMP-phosphodiesterases (PDE6s).
Zhang J; Kuvelkar R; Wu P; Egan RW; Billah MM; Wang P
Biochem Pharmacol; 2004 Sep; 68(5):867-73. PubMed ID: 15294449
[TBL] [Abstract][Full Text] [Related]
20. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]